Transplant News and Research

RSS

Colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome

Cleveland Clinic researchers have found that colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome, the most common hereditary, adult-onset cause of colorectal cancer, as published in the online version of the Journal of Clinical Oncology.

16 Feb 2013

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.

16 Feb 2013

University of Granada’s melatonin gel effective against mucositis

Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction.

15 Feb 2013

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

In 2012, The Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) jointly issued the MF Challenge Grant , seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).

15 Feb 2013

Allografts better survive implantation into brains of immunocompetent research mice

Researchers at the Johns Hopkins University in Baltimore, Md., and the Mossakowski Medical Research Centre in Warsaw, Poland, have found that nonself-donated cells (allografts) better survive implantation into the brains of immunocompetent research mice when the grafts are injected into the striatum (STR) of the brain rather than injected into the forceps minor (FM) region.

14 Feb 2013

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013.

14 Feb 2013

New medication could help patients with renal tumours triggered by tuberous sclerosis

In collaboration with the Berlin TSC Centre, Charité - Universitätsmedizin Berlin has developed a new therapy for patients suffering from renal tumours associated with the rare genetic disease tuberous sclerosis (TSC).

13 Feb 2013

Burkitt lymphoma risk after transplantation highlighted

Solid organ transplant recipients have a significant risk for developing Burkitt lymphoma (BL), US researchers have found.

12 Feb 2013

Donor liver quality: an interview with Dr Eric Orman

Liver transplantation is a surgical procedure in which a liver (or part of a liver) is removed from a donor and placed into a recipient. Although some transplants use a portion of the liver of living donors, the vast majority of donors are deceased.

6 Feb 2013

Viracor-IBT Laboratories signs definitive agreement to purchase assets of Cylex

Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.

5 Feb 2013

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

Orphan, St George's sign licensing agreement to develop new therapies for metabolic disorders

St George's, University of London has signed an exclusive worldwide licensing agreement with rare-disease research-and-development firm Orphan Technologies Ltd to develop new therapies for deadly metabolic disorders.

5 Feb 2013

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology

5 Feb 2013

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications.

1 Feb 2013

Notch protein responsible for activating GATA2 gene to generate hematopoietic stem cells

Researchers from the group on stem cells and cancer at IMIM (Hospital del Mar Medical Research Institute) have deciphered one of the gene regulation circuits which would make it possible to generate hematopoietic blood cells, i.e. blood tissue stem cells.

1 Feb 2013

Family history one of the strongest predictors of heart disease

Sherron Simmons lived her life as the picture of good health: she exercised regularly, ate healthy and did not smoke. That is why it was a shock for her to learn in 2007 that the main left artery to her heart was 90 percent blocked.

1 Feb 2013

EUROSTAM, AbSorber receive 2.6M grant as part of European Commission FP7

Allenex announces that Allenex group company AbSorber, together with EUROSTAM, a consortium of European Transplant Centers, has been supported by a € 2.6 million grant as part of the European Commission 7th framework programme (FP7).

1 Feb 2013

African-Americans without private health insurance less likely to receive kidney transplants

African-Americans and individuals without private health insurance are less likely than others to receive a kidney transplant before requiring dialysis, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

1 Feb 2013

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.

31 Jan 2013

Left ventricular assist device improves quality of life in two brothers with Becker's Muscular Dystrophy

Tyler Wertz, 18, and his 16-year old brother Austin Tucker, fight, tease, love and support each other like most brothers do. Unlike most brothers, however, they share the same uncertain future—both have heart assist devices keeping them alive while they struggle with a debilitating disease. As young boys, Tyler and Austin were diagnosed with Becker's Muscular Dystrophy, a disease that slowly weakens the arms and legs and damages the heart.

31 Jan 2013

Transplant News and Research

Colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

University of Granada’s melatonin gel effective against mucositis

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

Allografts better survive implantation into brains of immunocompetent research mice

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

New medication could help patients with renal tumours triggered by tuberous sclerosis

Burkitt lymphoma risk after transplantation highlighted

Donor liver quality: an interview with Dr Eric Orman

Viracor-IBT Laboratories signs definitive agreement to purchase assets of Cylex

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Orphan, St George's sign licensing agreement to develop new therapies for metabolic disorders

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Notch protein responsible for activating GATA2 gene to generate hematopoietic stem cells

Family history one of the strongest predictors of heart disease

EUROSTAM, AbSorber receive 2.6M grant as part of European Commission FP7

African-Americans without private health insurance less likely to receive kidney transplants

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Left ventricular assist device improves quality of life in two brothers with Becker's Muscular Dystrophy

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News